| Original Articles : Carboplatin, ifosfamide, and etoposide chemotherapy for extensive-disease small cell lung cancer |
|
Hee Juang Ryu, Young Nam Kim, Seon Yeong Gyeong, Se Hoon Park, Chang Hyeok An, Soo Mee Bang, Sang Pyo Lee, Jae Ik Lee, Jeong Ung Park, Eun Kyung Cho, Seong Hwan Jeong, Dong Bok Shin, Jae Hoon Lee |
|
한림의대 한강성심병원 내과 |
| 원저 : 확장기 소세포 폐암에서 Carboplatin, Ifosfamide, Etoposide 복합화학요법의 효과 |
|
류희정, Young Nam Kim, Seon Yeong Gyeong, Se Hoon Park, Chang Hyeok An, Soo Mee Bang, Sang Pyo Lee, Jae Ik Lee, Jeong Ung Park, Eun Kyung Cho, Seong Hwan Jeong, Dong Bok Shin, Jae Hoon Lee |
|
|
|
|
|
|
| Abstract |
Background : This prospective phase II study assessed the efficacy and toxicity of the combination of carboplatin, ifosfamide and etoposide for previously untreated patients with extensive-disease small cell lung cancer (ED-SCLC).
Methods
: Patients with ED-SCLC received a combination chemotherapy with carboplatin AUC 6.0 on day 1, ifosfamide 1200 mg/m2 on day 1-3, and etoposide 100 mg/m2 on day 1-3.
Results
: Forty-one patients received a median of six cycles of chemotherapy. A complete response was seen in 5 patients and a partial response was seen in 33 patients (overall response 95%). The median duration of the response was 5.1 months (95% CI; 3.4-6.8 months). The median time to progression and overall survival were 7.4 months (95% CI; 6.1-8.6 months) and 10.7 months (95% CI; 6.9-14.6 months), respectively, providing the one-year survival rate of 43.9%. Grade 3～4 anemia, neutropenia and thrombocytopenia occurred in 14%, 7% and 6% in a total of 212 cycles, respectively. Non-hematologic toxicities were generally mild and manageable. No treatment related death was observed.
Conclusions
: The combination chemotherapy of carboplatin, etoposide and ifosfamide showed an effective response rate and acceptable toxicity.(Korean J Med 70:688-694, 2006)
Key Words : Ifosfamide, Etoposide, Carboplatin, Small cell lung carcinoma |
|
PDF Links
Full text via DOI
Download Citation
